Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
Enveric Biosciences, Inc. (ENVB)
Company Research
Source: Business Wire
Selection of EB-003 based on research indicating its non-hallucinogenic, anxiolytic and anti-depressant properties CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it is presenting research describing the Company’s identification of EB-003 as its lead development candidate based on preclinical data suggesting the compound exhibits promising anxiolytic and anti-depressant properties without inducing hallucinations, a favorable profile compared with other analogs of N,N-Dimethyltryptamine (DMT). The poster is being presented by Peter Facchini, Ph.D. Chief Innovation Officer of Enveric at the European Behavioral Pharmacology Society Biennial Workshop being held in Banff, Alberta, Canada on September 26, 2024.The presentation titled, “Semi-syst
Show less
Read more
Impact Snapshot
Event Time:
ENVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENVB alerts
High impacting Enveric Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ENVB
News
- Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003Business Wire
- Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug SummitBusiness Wire
- Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
- Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other ConditionsBusiness Wire
- Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate ResultsBusiness Wire
ENVB
Sec Filings
- 10/11/24 - Form 4
- 10/11/24 - Form 4
- 10/11/24 - Form 4
- ENVB's page on the SEC website